{"id":390549,"date":"2018-11-16T00:00:00","date_gmt":"2018-11-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0003-2018-biopharma-chronic-obstructive-pulmonary-disease-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-03-31T10:47:46","modified_gmt":"2026-03-31T10:47:46","slug":"dlsfim0003-2018-biopharma-chronic-obstructive-pulmonary-disease-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0003-2018-biopharma-chronic-obstructive-pulmonary-disease-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>The\u00a0<abbr data-original-title=\"chronic obstructive pulmonary disease\" title=\"\">COPD<\/abbr>\u00a0market is continuing its gradual shift away from\u00a0<abbr data-original-title=\"long-acting\" title=\"\">LA<\/abbr>BA\/<abbr data-original-title=\"inhaled corticosteroid\" title=\"\">ICS<\/abbr><abbr data-original-title=\"fixed-dose combination\" title=\"\">FDC<\/abbr>s toward\u00a0<abbr data-original-title=\"long-acting beta2 agonist\" title=\"\">LABA<\/abbr>\/<abbr data-original-title=\"long-acting muscarinic antagonist\" title=\"\">LAMA\u00a0<\/abbr><abbr data-original-title=\"fixed-dose combination\" title=\"\">FDC<\/abbr>s, but current and emerging generics will have a significant impact on this trend. Some branded-generic and generic\u00a0<abbr data-original-title=\"long-acting beta2 agonist\" title=\"\">LABA<\/abbr>\/<abbr data-original-title=\"inhaled corticosteroid\" title=\"\">ICS<\/abbr><abbr data-original-title=\"fixed-dose combination\" title=\"\">FDC<\/abbr>s have already launched in the United States and Europe, and more will reach the market in the United States in the near future; given that cost remains a significant driver, competition from these generics is expected to impact uptake of both\u00a0<abbr data-original-title=\"long-acting beta2 agonist\" title=\"\">LABA<\/abbr>\/<abbr data-original-title=\"long-acting muscarinic antagonist\" title=\"\">LAMA<\/abbr>s and emerging\u00a0<abbr data-original-title=\"long-acting beta2 agonist\" title=\"\">LABA<\/abbr>\/<abbr data-original-title=\"long-acting muscarinic antagonist\" title=\"\">LAMA<\/abbr>\/<abbr data-original-title=\"inhaled corticosteroid\" title=\"\">ICS<\/abbr><abbr data-original-title=\"fixed-dose combination\" title=\"\">FDC<\/abbr>s. Physicians are eager to have alternative treatments for this chronic disease as development of novel drug classes continues in\u00a0<abbr data-original-title=\"chronic obstructive pulmonary disease\" title=\"\">COPD<\/abbr>.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>How will markets react to the launch of generic\u00a0<abbr data-original-title=\"long-acting beta2 agonist\" title=\"\">LABA<\/abbr>\/<abbr data-original-title=\"inhaled corticosteroid\" title=\"\">ICS<\/abbr><abbr data-original-title=\"fixed-dose combination\" title=\"\">FDC<\/abbr>s and tiotropium? Will there be significant country-to-country differences in uptake of these generics?<\/li>\n<li>Will\u00a0<abbr data-original-title=\"long-acting beta2 agonist\" title=\"\">LABA<\/abbr>\/<abbr data-original-title=\"long-acting muscarinic antagonist\" title=\"\">LAMA<\/abbr><abbr data-original-title=\"fixed-dose combination\" title=\"\">FDC<\/abbr>s continue to gain market share, or will generic therapies or branded\u00a0<abbr data-original-title=\"long-acting beta2 agonist\" title=\"\">LABA<\/abbr>\/<abbr data-original-title=\"long-acting muscarinic antagonist\" title=\"\">LAMA<\/abbr>\/<abbr data-original-title=\"inhaled corticosteroid\" title=\"\">ICS<\/abbr><abbr data-original-title=\"fixed-dose combination\" title=\"\">FDC<\/abbr>s threaten these agents?<\/li>\n<li>What proportion of patients currently receive a combination of two or more therapies in separate inhalers? How many receive triple therapy, and will these patients be shifted to\u00a0<abbr data-original-title=\"fixed-dose combination\" title=\"\">FDC<\/abbr>s?<\/li>\n<li>Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390549","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390549\/revisions"}],"predecessor-version":[{"id":576691,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390549\/revisions\/576691"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}